Nichi-Iko Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2022. For the period the company expects revenue of JPY 185,000 million, core operating loss of JPY 11,900 million, operating loss of JPY 17,100 million, loss attributable to owners of parent of JPY 18,600 million or basic loss per share of JPY 275.39.